Human Smad4 Matched Antibody Pair Kit (ab221430)
Key features and details
- Unlabeled capture antibody, biotin-labeled detection antibody and calibrated protein standard
- For economical ELISA and ELISA-based assay development
- Reacts with: Human
- Range: 781.25 pg/ml - 50000 pg/ml
Overview
-
Product name
Human Smad4 Matched Antibody Pair Kit
See all Smad4 kits -
Detection method
Colorimetric -
Assay type
ELISA set -
Sensitivity
79.4 pg/ml -
Range
781.25 pg/ml - 50000 pg/ml -
Species reactivity
Reacts with: Human -
Product overview
Human Smad4 Matched Antibody Pair Kits include a capture and a biotinylated detector antibody pair, along with a calibrated protein standard, suitable for sandwich ELISA. The Matched Antibody Pair Kit can be used to quantify native and recombinant human Smad4.
Optimization of the kit reagents to sample type, immunoassay format or instrumentation may be required. Guidelines for use of this kit in a standard 96-well microplate sandwich ELISA using HRP/TMB system of colorimetric detection is described in this assay procedure for the purposes of quantification.
Protocol information and tips on the use of the Matched Antibody Pair kits for sandwich ELISA can be found on our website. An accessory pack can be purchased which includes buffer reagents required to perform 10 x 96-well plate sandwich ELISAs (ab210905).
-
Tested applications
Suitable for: ELISAmore details -
Platform
Reagents
Properties
-
Storage instructions
Store at -20°C. Please refer to protocols. -
Components 10 x 96 tests 5 x 96 tests Human Smad4 Capture Antibody 2 x 50µg 1 x 50µg Human Smad4 Detector Antibody 2 x 12.5µg 1 x 12.5µg Human Smad4 Lyophilized Protein 2 vials 1 vial -
Research areas
-
Function
Common SMAD (co-SMAD) is the coactivator and mediator of signal transduction by TGF-beta (transforming growth factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that forms in the nucleus and is required for the TGF-mediated signaling. Promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. Component of the multimeric SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site; required for syngernistic transcriptional activity in response to TGF-beta. May act as a tumor suppressor. -
Involvement in disease
Defects in SMAD4 are a cause of pancreatic cancer (PNCA) [MIM:260350].
Defects in SMAD4 are a cause of juvenile polyposis syndrome (JPS) [MIM:174900]; also known as juvenile intestinal polyposis (JIP). JPS is an autosomal dominant gastrointestinal hamartomatous polyposis syndrome in which patients are at risk for developing gastrointestinal cancers. The lesions are typified by a smooth histological appearance, predominant stroma, cystic spaces and lack of a smooth muscle core. Multiple juvenile polyps usually occur in a number of Mendelian disorders. Sometimes, these polyps occur without associated features as in JPS; here, polyps tend to occur in the large bowel and are associated with an increased risk of colon and other gastrointestinal cancers.
Defects in SMAD4 are a cause of juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome (JP/HHT) [MIM:175050]. JP/HHT syndrome phenotype consists of the coexistence of juvenile polyposis (JIP) and hereditary hemorrhagic telangiectasia (HHT) [MIM:187300] in a single individual. JIP and HHT are autosomal dominant disorders with distinct and non-overlapping clinical features. The former, an inherited gastrointestinal malignancy predisposition, is caused by mutations in SMAD4 or BMPR1A, and the latter is a vascular malformation disorder caused by mutations in ENG or ACVRL1. All four genes encode proteins involved in the transforming-growth-factor-signaling pathway. Although there are reports of patients and families with phenotypes of both disorders combined, the genetic etiology of this association is unknown.
Defects in SMAD4 may be a cause of colorectal cancer (CRC) [MIM:114500]. -
Sequence similarities
Belongs to the dwarfin/SMAD family.
Contains 1 MH1 (MAD homology 1) domain.
Contains 1 MH2 (MAD homology 2) domain. -
Domain
The MH1 domain is required for DNA binding.
The MH2 domain is required for both homomeric and heteromeric interactions and for transcriptional regulation. Sufficient for nuclear import. -
Post-translational
modificationsMonoubiquitinated on Lys-519 by E3 ubiquitin-protein ligase TRIM33. Monoubiquitination hampers its ability to form a stable complex with activated SMAD2/3 resulting in inhibition of TGF-beta/BMP signaling cascade. Deubiqitination by USP9X restores its competence to mediate TGF-beta signaling. -
Cellular localization
Cytoplasm. Nucleus. Cytoplasmic in the absence of ligand. Migrates to the nucleus when complexed with R-SMAD. - Information by UniProt
-
Alternative names
- (Small) Mothers Against Decapentaplegic
- Deleted in Pancreatic Carcinoma
- Deleted in Pancreatic Carcinoma 4
see all -
Database links
- Entrez Gene: 4089 Human
- Omim: 600993 Human
- SwissProt: Q13485 Human
- Unigene: 75862 Human
Images
-
Standard calibration curve. Background subtracted values are graphed.
-
To learn more about the advantages of recombinant antibodies see here.